Passage Bio, Inc. Gains 46.36%
Thu, Jan 02, 2025 at 07:09 PM
Passage Bio, Inc. (PASG:NASDAQ) rocketted at $0.83, representing a gain of 46.4%. On Thu, Jan 02, 2025, PASG:NASDAQ hit a New 2-Week High of $0.83. The stock appeared on our News Catalysts scanner on Fri, Dec 13, 2024 at 08:50 PM in the 'BIOTECH' category. From Thu, Dec 19, 2024, the stock recorded 62.50% Up Days and 66.67% Green Days
The stock spiked on Fri, Nov 29, 2024 at $1.33 with a volume of 15M+.
About Passage Bio, Inc. (PASG:NASDAQ)
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Top 10 Gainers:
- N2OFF Inc. (NITO:NASDAQ), 331.45%
- Carmell Therapeutics Corporation Class A Common Stock (CTCX:NASDAQ), 140.06%
- Smart for Life Inc. (SMFL:NASDAQ), 132.18%
- TherapeuticsMD, Inc. (TXMD:NASDAQ), 82.54%
- Crown LNG Holdings Limited (CGBS:NASDAQ), 69.48%
- SuperCom Ltd. (SPCB:NASDAQ), 59.34%
- Quantum-Si Incorporated (QSI:NASDAQ), 57.78%
- Heartcore Enterprises Inc. (HTCR:NASDAQ), 56.47%
- Faraday Future Intelligent Electric Inc. (FFIE:NASDAQ), 51.85%
- Passage Bio, Inc. (PASG:NASDAQ), 46.36%